PAI-1 is a serine protease inhibitor and contributes to renal fibrosis via negative actions through urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) with subsequently low intracellular plasmin. This evidence concerns the gene PLAU and renal fibrosis.